CD274 and non-small cell lung carcinoma: Advanced NSCLC with PD‐L1 ≥ 50%;In combination with pemetrexed and carboplatin for advanced nonsquamous NSCLC;In combination with carboplatin and paclitaxel (nab‐paclitaxel) for advanced squamous NSCLC